ORIGINAL
Seguridad y efectividad del tratamiento con hormona de crecimiento: estudio GeNeSIS en España
Safety and efficacy of growth hormone treatment: GeNeSIS study in Spain
C. Luzuriaga Tomása, M. Oyarzabal Irigoyenb, E. Caveda Cepasc, L.A. Vázquez Salvid, L.E. García-Péreze,
, el grupo de investigadores españoles del estudio GeNeSIS
Autor para correspondencia
a Unidad de Endocrinología Pediátrica, Hospital Marqués de Valdecilla, Santander, Cantabria, España
b Unidad de Endocrinología Pediátrica, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
c Global Scientific Communications, Eli Lilly and Company, Alcobendas Madrid, España
d Departamento Médico, Eli Lilly and Company, Alcobendas Madrid, España
e Global Medical Affairs, Eli Lilly and Company, Indianapolis, USA
Leído
21320
Vecesse ha leído el artículo
3490
Total PDF
17830
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 205 | 39 | 244 |
| 2025 5 | 434 | 44 | 478 |
| 2025 4 | 429 | 41 | 470 |
| 2025 3 | 489 | 37 | 526 |
| 2025 2 | 429 | 45 | 474 |
| 2025 1 | 423 | 44 | 467 |
| 2024 12 | 369 | 62 | 431 |
| 2024 11 | 387 | 80 | 467 |
| 2024 10 | 304 | 50 | 354 |
| 2024 9 | 308 | 58 | 366 |
| 2024 8 | 304 | 69 | 373 |
| 2024 7 | 207 | 33 | 240 |
| 2024 6 | 249 | 47 | 296 |
| 2024 5 | 219 | 47 | 266 |
| 2024 4 | 257 | 51 | 308 |
| 2024 3 | 230 | 41 | 271 |
| 2024 2 | 218 | 39 | 257 |
| 2024 1 | 295 | 36 | 331 |
| 2023 12 | 272 | 77 | 349 |
| 2023 11 | 239 | 39 | 278 |
| 2023 10 | 229 | 23 | 252 |
| 2023 9 | 176 | 23 | 199 |
| 2023 8 | 180 | 26 | 206 |
| 2023 7 | 227 | 26 | 253 |
| 2023 6 | 150 | 42 | 192 |
| 2023 5 | 203 | 32 | 235 |
| 2023 4 | 114 | 24 | 138 |
| 2023 3 | 174 | 23 | 197 |
| 2023 2 | 135 | 29 | 164 |
| 2022 1 | 105 | 19 | 124 |
| 2022 12 | 125 | 41 | 166 |
| 2022 11 | 179 | 64 | 243 |
| 2022 10 | 155 | 49 | 204 |
| 2022 9 | 105 | 57 | 162 |
| 2022 8 | 119 | 47 | 166 |
| 2022 7 | 102 | 41 | 143 |
| 2022 6 | 142 | 45 | 187 |
| 2022 5 | 134 | 49 | 183 |
| 2022 4 | 169 | 38 | 207 |
| 2022 3 | 172 | 53 | 225 |
| 2022 2 | 193 | 30 | 223 |
| 2021 1 | 189 | 37 | 226 |
| 2021 12 | 112 | 38 | 150 |
| 2021 11 | 156 | 49 | 205 |
| 2021 10 | 139 | 55 | 194 |
| 2021 9 | 114 | 40 | 154 |
| 2021 8 | 121 | 54 | 175 |
| 2021 7 | 125 | 57 | 182 |
| 2021 6 | 130 | 56 | 186 |
| 2021 5 | 153 | 74 | 227 |
| 2021 4 | 336 | 108 | 444 |
| 2021 3 | 235 | 34 | 269 |
| 2021 2 | 132 | 46 | 178 |
| 2020 1 | 129 | 35 | 164 |
| 2020 12 | 127 | 27 | 154 |
| 2020 11 | 96 | 36 | 132 |
| 2020 10 | 121 | 20 | 141 |
| 2020 9 | 116 | 17 | 133 |
| 2020 8 | 115 | 21 | 136 |
| 2020 7 | 123 | 22 | 145 |
| 2020 6 | 128 | 16 | 144 |
| 2020 5 | 141 | 36 | 177 |
| 2020 4 | 132 | 21 | 153 |
| 2020 3 | 129 | 32 | 161 |
| 2020 2 | 111 | 16 | 127 |
| 2020 1 | 108 | 24 | 132 |
| 2019 12 | 141 | 25 | 166 |
| 2019 11 | 135 | 18 | 153 |
| 2019 10 | 210 | 25 | 235 |
| 2019 9 | 207 | 36 | 243 |
| 2019 8 | 185 | 28 | 213 |
| 2019 7 | 146 | 17 | 163 |
| 2019 6 | 149 | 23 | 172 |
| 2019 5 | 225 | 41 | 266 |
| 2019 4 | 902 | 29 | 931 |
| 2019 3 | 393 | 17 | 410 |
| 2019 2 | 106 | 21 | 127 |
| 2019 1 | 96 | 11 | 107 |
| 2018 12 | 107 | 24 | 131 |
| 2018 11 | 195 | 44 | 239 |
| 2018 10 | 309 | 61 | 370 |
| 2018 9 | 129 | 35 | 164 |
| 2018 8 | 2 | 0 | 2 |
| 2018 7 | 3 | 0 | 3 |
| 2018 6 | 5 | 0 | 5 |
| 2018 5 | 17 | 0 | 17 |
| 2018 4 | 51 | 0 | 51 |
| 2018 3 | 64 | 0 | 64 |
| 2018 2 | 33 | 0 | 33 |
| 2018 1 | 51 | 1 | 52 |
| 2017 12 | 53 | 0 | 53 |
| 2017 11 | 35 | 0 | 35 |
| 2017 10 | 47 | 1 | 48 |
| 2017 9 | 38 | 0 | 38 |
| 2017 8 | 39 | 0 | 39 |
| 2017 7 | 43 | 1 | 44 |
| 2017 6 | 38 | 16 | 54 |
| 2017 5 | 94 | 13 | 107 |
| 2017 4 | 34 | 14 | 48 |
| 2017 3 | 50 | 17 | 67 |
| 2017 2 | 43 | 5 | 48 |
| 2016 1 | 22 | 9 | 31 |
| 2016 12 | 39 | 14 | 53 |
| 2016 11 | 61 | 13 | 74 |
| 2016 10 | 67 | 23 | 90 |
| 2016 9 | 77 | 18 | 95 |
| 2016 8 | 62 | 14 | 76 |
| 2016 7 | 43 | 19 | 62 |
| 2016 5 | 1 | 0 | 1 |
| 2016 4 | 2 | 0 | 2 |
| 2016 3 | 8 | 126 | 134 |
Mostrar todo
